Something New to Help Prevent Covid-19

Mechanical barriers to prevent the penetration of the Covid 19 virus into the mucous membranes of the nasal passages have been studies extensively. Using saline washes may reduce the viral load and reduce the risk of infection. Here is the latest, azelastine, an over-the-counter antihistamine marketed as Astelin or Astepro may reduce the risk of getting infected if used three times daily according to an article published today in JAMA. It might be most practical to use when traveling during surges. It can cause drowsiness and has a bitter taste which can limit its use.

Key PointsQuestion Is regular application of azelastine nasal spray associated with reduced risk of SARS-CoV-2 infections?

Findings In this randomized placebo-controlled clinical trial that included 450 participants, the incidence of laboratory-confirmed SARS-CoV-2 infections was significantly lower with application of azelastine nasal spray compared with placebo treatment.

Meaning The use of azelastine nasal spray may help to reduce the risk of SARS-CoV-2 infections.

Abstract

Importance Limited pharmaceutical options exist for preexposure prophylaxis of COVID-19 beyond vaccination. Azelastine, an antihistamine nasal spray used for decades to treat allergic rhinitis, has in vitro antiviral activity against respiratory viruses, including SARS-CoV-2.

Objective To determine the efficacy and safety of azelastine nasal spray for prevention of SARS-CoV-2 infections in healthy adults.

Design, Setting, and Participants A phase 2, double-blind, placebo-controlled, single-center trial was conducted from March 2023 to July 2024. Healthy adults from the general population were enrolled at the Saarland University Hospital in Germany.

Interventions Participants were randomly assigned 1:1 to receive azelastine, 0.1%, nasal spray or placebo 3 times daily for 56 days. SARS-CoV-2 rapid antigen testing (RAT) was conducted twice weekly, with positive results confirmed by polymerase chain reaction (PCR). Symptomatic participants with negative RAT results underwent multiplex PCR testing for respiratory viruses.

Main Outcome The primary end point was the number of PCR-confirmed SARS-CoV-2 infections during the study.

Results A total of 450 participants were randomized, with 227 assigned to azelastine and 223 to placebo; 299 (66.4%) were female, 151 (33.6%) male, with a mean (SD) age of 33.0 (13.3) years. Most were White (417 [92.7%]), with 4 (0.9%) African, 22 (4.9%) Asian, and 7 (1.6%) of other ethnicity. In the intention-to-treat (ITT) population, the incidence of PCR-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group (n = 5 [2.2%]) compared with the placebo group (n = 15 [6.7%]) (OR, 0.31; 95% CI, 0.11-0.87). As secondary end points, azelastine demonstrated an increase in mean (SD) time to SARS-CoV-2 infection among infected participants (31.2 [9.3] vs 19.5 [14.8] days), a reduction of the overall number of PCR-confirmed symptomatic infections (21 of 227 participants vs 49 of 223 participants), and a lower incidence of PCR-confirmed rhinovirus infections (1.8% vs 6.3%). Adverse events were comparable between the groups.

Conclusions and Relevance In this single-center trial, azelastine nasal spray was associated with reduced risk of SARS-CoV-2 respiratory infections. These findings support the potential of azelastine as a safe prophylactic approach warranting confirmation in larger, multicentric trials.

Trial registration EudraCT number: 2022-003756-13

Something New to Help Prevent Covid-19

Azelastine Nasal Spray for Prevention of SARS-CoV-2 InfectionsA Phase 2 Randomized Clinical Trial

Related posts